Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response study of sublingual birch pollen allergy immunotherapy tablet
NL-OMON39055Phase 2Active, not recruiting
- Sponsor
- ALK-Abelló
- Start
- Aug 2012
- Countries
- 1
01
Overview
Phase 2 trial of birch pollen extract in birch pollen allergy and allergic rhinoconjunctivitis (ARC), sponsored by ALK-Abelló. Primary endpoint: Average daily rhinoconjunctivitis symptom score during the entire birch pollen season. Started Aug 2012; status: active, not recruiting.
02
Drugs
birch pollen extract
03
Conditions
birch pollen allergyallergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NL-OMON39055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39055.